+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton pump inhibitors as a treatment method for type II diabetes

Proton pump inhibitors as a treatment method for type II diabetes

Medical Hypotheses 73(1): 29-32

Recent reports have hypothesized a role for exogenously administered gastrin in regulating beta cell function or activity. We surmised that a class of agents, proton pump inhibitors (omeprazole, esomeprazole, pantoprazole, rabeprazole, lansoprazole), known to increase serum gastrin levels could have such an effect, and that data might be available in our database which could address such an effect. We examined our electronic database to obtain glycohemoglobin (HgbA1c) levels measured in the past two years from all type II diabetics and extracted from those diabetics who were concurrently taking a proton pump inhibitor. A comparison of these groups showed an average HgbA1c of 7.6% for type II diabetics not taking a proton pump inhibitor (n=282) and an average HgbA1c of 7.0% for type II diabetics concurrently taking a proton pump inhibitor (n=65), T=-3.61, p=0.002. These data support the hypothesis that proton pump inhibitors can be used to treat type II diabetes.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260347

Download citation: RISBibTeXText

PMID: 19304401

DOI: 10.1016/j.mehy.2009.02.010

Related references

Proton pump inhibitors and nitric oxide mechanisms in type 2 diabetes. Diabetologia 56(12): 2763-2764, 2014

The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus. Canadian Journal of Diabetes 39(1): 24-28, 2015

Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. Acta Diabetologica 52(5): 873-880, 2015

Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type. Eksperimental'naia i Klinicheskaia Gastroenterologiia 2): 35-6, 101, 2002

Prevention of stress induced ulcers: histamine-2 receptor antagonists or proton pump inhibitors? - gastric hemorrhage occur more often under proton pump inhibitors. Deutsche Medizinische Wochenschrift 139(25-26): 1338-1338, 2014

Hypersensitivity to lansoprazole with tolerance to other proton pump inhibitors: does cross-reactivity between proton pump inhibitors really exist?. Allergologia et Immunopathologia 41(2): 136-137, 2013

Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort Study. Plos One 10(8): E0135915-E0135915, 2016

The relationship between type 2 diabetes mellitus and failure to proton pump inhibitor treatment in gastroesophageal reflux disease. Journal of Clinical Gastroenterology 46(8): 662-668, 2013

Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 53(10): 2220-2223, 2011

Clinical Meditation and Imagery in Holistic Mental Health Care. Beginnings 36(6): 18-20, 2016

Case report of proton pump inhibitor responsive esophageal eosinophilia: why 2 months of proton pump inhibitors is required. Diseases of the Esophagus 29(6): 700-703, 2014

Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole. Biochemical Pharmacology 58(8): 1349-1359, Oct 15, 1999

Increased use of proton pump inhibitors in patients with diabetes and neuropathy. Endocrine Practice 15(6): 653-654, 2010

Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clinical Gastroenterology and Hepatology 12(11): 1815-23.E2, 2015

Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. Journal of Gastroenterology 46(1): 39-45, 2011